ArticlemedRxiv : the preprint server for health sciences2025
Probability of vertical HIV transmission: A systematic review and meta-regression.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
15 authors.
Funding
Abstract
Background: Eliminating HIV vertical transmission (VT) is a global priority and monitored by estimating paediatric HIV infections with the Joint United Nations Programme on HIV/AIDS supported Spectrum AIDS Impact Module (Spectrum-AIM). Recent innovations in antiretroviral therapy (ART) service delivery models and first-line regimens aimed to reduce VT probabilities. We conducted a systematic review and meta-analysis to estimate VT probabilities by maternal immunologic and treatment status. Methods: We combined an updated systematic review with previous data in meta-regression models to estimate VT probabilities and determinants. We searched multiple databases for peer-reviewed English-language studies from all regions published between January 2018 and February 2024 with VT data stratified by maternal immunologic or treatment status from randomized trials, cohort, or observational studies. Four meta-regression models estimated VT probabilities. We assessed model sensitivity and compared estimates to Spectrum-AIM's previous results. Finally, we fit a meta-regression model to assess the association of ART class and initiation timing on viral load suppression (VLS) at delivery. Findings: The updated review identified 24 new studies, yielding 110 total studies included in meta-regression analysis. For women not receiving ART, higher CD4 was associated with lower odds of perinatal VT (odds ratio [OR] 0.80 (95% CI: 0.75-0.84) per 100 CD4 cells/μL increase). For pregnant women on ART, each additional week on ART before delivery reduced odds of VT by 5.6% (3.2%-7.0%). The odds ratio of perinatal VT among pregnant women initiating integrase inhibitor-based ART 20 weeks pre-delivery was 0.36 (0.14-0.94) compared to those initiating non-nucleoside reverse transcriptase inhibitors (NNRTI)-based ART. This association was confounded by study region. Odds of VLS were lower when ART was initiated late in pregnancy (OR: 0.37 (0.21-0.68) for the reference regimen (NNRTI)), without significant difference by ART regimen. Interpretation: VT probability varies by maternal immunologic stage, treatment regimen, and timing of treatment initiation. These estimates have been incorporated into Spectrum-AIM for UNAIDS 2025 HIV estimates. Earlier ART initiation is associated with higher odds of VLS at delivery. Further evidence is needed on the effects of recent ART innovations on VT outcomes. Funding: NIH, UNAIDS, and UKRI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.